Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03993379
Title PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors CytomX Therapeutics
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | NLD | ESP | AUS


No variant requirements are available.